Earnings Call Presentation Q1/2023

AGENDA

01 _ Overview

02 _ Key Figures Q1/2023

03 _ Outlook 2023

04 _ Appendix

01 Overview



Highlights im First Quarter 2023

Revenue growth of 15.6% to EUR 27.6 million due to volume increases as well as price increases (carryover effect from 2022).


Order backlog further increased to EUR 24.2 million as of 31.03.2023 (31.12.2022: EUR 22.8 million).

Operative consolidated-EBIT with plus 35.2% at EUR 4.1 million.

Strong demand dynamics in the aviation business, life science and semiconductor technology sectors - growth of all subsidiaries in Q1.

Operative EBIT-Margin further improved to 15% - due to volume growth and more favourable product mix.

Balance sheet quality further improved Despite growth-related increase in working capital and expansion of total assets, equity ratio rises to 58.5%.



02 Key Figures

Q1/2023

Key Figures Q1/2023

in million EUR	Q1/2023	Q1/2022	Change
Revenue	27.6	23.9	+15.6%
EBITDA	5.4	4.3	+26.7%
EBIT (operative)	4.1	3.1	+35.2%
Consolidated result	3.4	2.1	+62.3%
EPS (in EUR)	0.36	0.22	+63.6%




Convincing start to the year 2023

- Revenue increased by 15.6% in the first quarter due to volume as well as price increases.
- Group operating EBIT rises by more than a third to EUR 4.1 million - positive margin effect from volume growth and product mix with disproportionately low increase in personnel costs.
- Operating EBIT margin further improved quarter-on-quarter to 15.0%.
- Consolidated net income with significant increase of 62.3% to EUR 3.4 million.

Rising Group Equity in the first quarter 2023


Group equity and equity ratio

in EUR million



Dividend/EPS

in EUR





Equity ratio further increased


- Group equity increases by EUR 3.3 million to EUR 55.3 million (31.12.2022: EUR 52.0 million) due to positive earnings situation.
- Decrease in cash and cash equivalents as at 31.03.2023 to EUR 8.2 million (31.12.2022: EUR 9.6 million) - reflects working capital build-up as well as payments of management bonuses, bonuses and insurance premiums.
- Positive operating cash flow of EUR 0.4 million as of 31.03.2023 (Q1/2022: EUR 0.8 million).
- Earnings per share increase by 63.6% to EUR 0.36 (previous year: EUR 0.22).


MASTERFLEX GROUP

Page 07


Masterflex share and dividend information

Development of the share price from January 2023 to April 2023 in EUR (on Xetra basis)









Montega Research 08.04.2023

BUY - EUR 16.00




SMC Research 04.04.2023

BUY - EUR 14.00



Metzler 21.03.2023 BUY – EUR 12.50 03 Outlook

2023



Outlook 2023

Business development less susceptible to cyclical fluctuations by focusing on a wide range of industries

Sustained growth in core markets expected, increasing demand in medical technology, life science, mobility, aerospace and semiconductor industries

Revenue growth for the fiscal year 2023 expeted between EUR 103 million to EUR 110 million (2022: EUR 100.3 million)

Operating EBIT to increase to between EUR 11 million and EUR 14 million in 2023 (2022: EUR 11.4 million) - Stabilisation and further expansion of the yield level achieved


Solid order book - at EUR 24.2 million as at end-March 2023 and order intake remains robust. Geopolitical environment remains challenging.

Outlook Medium-term forecast



"The Company phase Ahead of us is marked by growth."

- Increasing digitalisation and further internationalisation coupled with organic and inorganic growth form the strategic basis for long-term growth
- Additional leverage through organic growth and acquisitions to revenue level of EUR 200 million by 2030 - focus shifts towards organic growth thanks to robust growth perspective
- Extended product and service range in the circular economy planned on the basis of our Ampius hose system - more detailed communication on this in early summer
- Further increase in profitability thanks to the use of economies of scale
- Focus on megatrends such as green energy, semiconductors, life science, medical technology and a suitable range of solutions ensures sustainable growth



04 Appendix

Masterflex at a glance

in thousand EUR	31.12.2017	31.12.2018	31.12.2019	31.12.2020	31.12.2021	31.12.2022
Revenue	74,675	77,243	79,969	71,881	79,068	100,274
EBITDA	10,263	9,592	9,656	7,892	10,670	16,436
EBIT (operating)	7,081	6,251	5,058	3,167	5,764	11,395
Group result	4,311	3,373	2,532	793	3,282	7,777
EPS (in EUR)	0.45	0.35	0.26	0.08	0.34	0.81

Financial Calendar 2023

7 June	Annual General Meeting 2023
9 August	Half-Year Report 2023
23 – 24 August	Hamburger Investors Day
8 November	Quarterly Statement 3/2023

Contact Investor Relation







Address

Phone

Online

Masterflex SE
Mark Becks, CFO
Willy-Brandt-Allee 300
45891 Gelsenkirchen

CROSS ALLIANCE
communication GmbH
Susan Hoffmeister
Bahnhofstr. 98
82166 Graefelfing/Munich

Phone.: +49 209 97077 0 Phone.: +49 89 125 09 03 33 Fax: +49 209 97077 33

ir@masterflexgroup.com

sh@crossalliance.de

Thank you